[1]
|
J. Desrame, H. Broustet, P. Darodes de Tailly, D. Girard and J. M. Saissy, “Oxaliplatin-Induced Haemolytic Anaemia,” Lancet, Vol. 354, No. 9185, 1999, pp. 1179-1180.
doi:10.1016/S0140-6736(99)03827-1
|
[2]
|
S. Buti, M. Riccò, M. D. Chiesa, B. Copercini, G. Tomasello, M. Brighenti and R. Passalacqua, “Oxaliplatin-Induced Hemolytic Anemia during Adjuvant Treatment of a Patient with Colon Cancer: A Case Report,” Anticancer Drugs, Vol. 18, No. 3, 2007, pp. 297-300.
doi:10.1097/CAD.0b013e3280102f4b
|
[3]
|
J. I. Lai, W. S. Wang “Acute Hemolysis after Receiving Oxaliplatin Treatment: A Case Report and Literature Review,” Pharmacy World & Science, Vol. 31, No. 5, 2009, pp. 538-541. doi:10.1007/s11096-009-9313-0
|
[4]
|
I. Ito, Y. Ito, M. Mizuno, Y. Suzuki, K. Yasuda, T. Ozaki, et al., “A Rare Case of Acute Kidney Injury Associated with Autoimmune Hemolytic Anemia and Thrombocytopenia after Long-Term Usage of Oxaliplatin,” Clinical and Experimental Nephrology, Vol. 16, No. 3, 2012, pp. 490-494. doi:10.1007/s10157-012-0620-8
|
[5]
|
A. Ulusakarya, S. Misra, M. Haydar, H. Habert, V. Castagne, Y. Gumus, et al., “Acute Renal Failure Related to Oxaliplatin-Induced Intravascular Hemolysis,” Medical Oncology, Vol. 27, No. 4, 2010, pp. 1425-1426.
doi:10.1007/s12032-009-9263-3
|
[6]
|
A. Salama, “Drug-Induced Immune Hemolytic Anemia,” Expert Opinion on Drug Safety, Vol. 8, No. 1, 2009, pp. 73-79. doi:10.1517/14740330802577351
|
[7]
|
G. Garratty, “Drug-Induced Immune Hemolytic Anemia,” Hematology ASH Education Program, Vol. 2009, No. 1, 2009, pp. 73-79.
|